Tranexamic Acid With Microneedling in Melasma

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Topical tranexamic, a hydrophilic molecule, can't pass the lipid barriers of the stratum corneum and it's also not retained in adequate amount in the epidermis to enter the melanocytes, so there's a difficulty in the effective delivery of tranexamic acid into the melanocytes .

Hyaluronic acid was proved to improve the effective delivery of tranexamic acid through loosening corneocyte packing and helping TXA entering the melanocytes and minimizing its epidermal diffusion .

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Hyaluronic Acid; Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients aged > 18 years.

• Both sexes.

• All types of melasma (epidermal, dermal and mixed).

• Nearly bilateral symmetrical melasma

Exclusion Criteria:

• Pregnancy and lactation

• Patients who are taking contraceptive pills at the time of the study or during the past 12 months.

• Patients with bleeding disorders with hypercoagulable state or the concomitant use of anticoagulants.

• Patient with history of thrombosis like DVT, coronary artery disease, stroke.

• Patient using any treatment for melasma during the past 1 month before the study.

• Active skin infection.

• Infection and immunosuppression

• Patient with keloidal tendency